HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 51–100 of 167 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07647263	Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer	recruiting	Phase 2	124	The First Affiliated Hospital of Soochow UniversityOTHER	1	Jun 15, 2026	clinicaltrials
NCT07635342	Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer	recruiting	Phase 2	182	Hebei Medical University Fourth HospitalOTHER	1	Jun 9, 2026	clinicaltrials